Vanguard Capital Management’s Xilio Therapeutics XLO Stock Holding History
Bought
Maintained
Sold
Other funds holding XLO
Vanguard Capital Management's XLO Position: Q3 2026 in Review
Vanguard Capital Management increased its Xilio Therapeutics (XLO) stake by 11% in Q3 2026, buying an estimated $178K and bringing the position to 198,181 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3395.
Vanguard Capital Management first reported a position in XLO in Q1 2026 and has held it in 3 quarters since. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2026.
- Vanguard Capital Management held 198,181 shares of Xilio Therapeutics worth $1.79M as of Q3 2026.
- Vanguard Capital Management bought 19,664 Xilio Therapeutics shares in Q3 2026, an estimated $178K.
- Xilio Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3395 holding.
- Vanguard Capital Management first reported a position in Xilio Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.